Abstract
Purpose
This prospective noncomparative observational study evaluated the clinical symptoms,
body weight and blood pressure of 38 adolescents receiving a monthly injectable contraceptive
containing estradiol valerate 5 mg and norethisterone 50 mg.
Methods
The volunteers, aged 16���19 years, were examined monthly during 1 year and asked
about the following symptoms at baseline: dysmenorrhea, headache, breast tenderness,
leg pain and irritability.
Results
There was a constant and gradual decline in each of the above symptoms over time,
and there was a statistically significant difference between symptoms reported at
the first visit and subsequent appointments. Body weight and blood pressure did not
change significantly during the 1-year period. No pregnancies were observed.
Conclusion
These findings suggest that monthly injectable contraception with estradiol valerate
5 mg/norethisterone 50 mg represents a highly effective and well-tolerated contraceptive
for teens.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A school-hospital and university-based adolescent pregnancy prevention program.J Reprod Med. 1984; 29: 421-426
- Oral contraceptive for the adolescent.J Reprod Med. 1984; 29: 551-559
- Bleeding patterns of adolescents using a combination contraceptive injection for 1 year.Contraception. 2006; 73: 594-597
- Medical eligibility criteria for contraceptive use. Reproductive health and research.3rd ed. WHO, Geneva2004
- Cigarette smoking, menstrual symptoms and miscarriage among young women.Aust N Z J Public Health. 2000; 24: 413-420
- Practical statistics for medical research. Chapman & Hall, London (England)1991: 250
- Mesigyna once-a-month combined injectable contraceptive: experience in Latin America.Contraception. 2000; 61: 309-316
- Once-a-month injectable contraceptives, Cyclofem and Mesigyna, in Egypt. Efficacy, causes of discontinuation, and side effects.Contraception. 1999; 60: 87-92
- Multicentred, Phase III clinical trial of norethisterone enanthate 50 mg plus estradiol valerate 5mg as a monthly injectable contraceptive; final three-year report.Contraception. 1994; 50: 329-337
- Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.Contraception. 1989; 39: 619-632
Article info
Publication history
Published online: May 26, 2007
Accepted:
March 12,
2007
Received in revised form:
January 18,
2007
Received:
December 16,
2006
Footnotes
���Financial support: the injections were provided, free of charge, by Schering Brasil (Schering, Berlin, Germany) to the Family Planning Clinic. No other funding was received, from Schering or any other industry or agency, in support of this research. There was no conflict of interest by any of the authors.
Identification
Copyright
© 2007 Published by Elsevier Inc.
